RNS Number : 1620H MaxCyte, Inc. 02 August 2021 MaxCyte Announces Full Exercise of Over-Allotment Option This announcement contains inside information GAITHERSBURG, MD , August 2, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT) (LSE: MXCT, MXCN) (" MaxCyte " or the " Company "), a leading
RNS Number : 1359H MaxCyte, Inc. 30 July 2021 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this
RNS Number : 1349H MaxCyte, Inc. 30 July 2021 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered
RNS Number : 0400H MaxCyte, Inc. 30 July 2021 MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market This announcement contains inside information GAITHERSBURG, MD , July 29, 2021 - MaxCyte, Inc.
RNS Number : 4538G MaxCyte, Inc. 26 July 2021 MaxCyte Announces Launch of Offering and Application to List on the Nasdaq Global Market This announcement contains inside information GAITHERSBURG, MD , July 26, 2021 - MaxCyte, Inc. , (LSE: MXCT, MXCN), a leading provider of platform
RNS Number : 6950F MaxCyte, Inc. 19 July 2021 Termination of depositary interest facility and transition to CREST depository interests GAITHERSBURG, MD , 19 July 2021 - MaxCyte, Inc. (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announces certain
RNS Number : 8366E MaxCyte, Inc. 12 July 2021 Financial information in the Form S-1 registration statement & Change to Board of Directors GAITHERSBURG, MD , 12 July 2021 - MaxCyte, Inc. , (LSE: MXCT, MXCN), a leading provider of platform technologies for cell engineering ("
RNS Number : 8357E MaxCyte, Inc. 12 July 2021 MaxCyte Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual Listing GAITHERSBURG, MD , July 12, 2021 - MaxCyte, Inc. , (LSE: MXCT, MXCN), a leading provider of platform technologies for cell engineering,
RNS Number : 3656E MaxCyte, Inc. 06 July 2021 Result of Special Meeting GAITHERSBURG, MD , 06 July 2021 - MaxCyte, Inc. , (LSE: MXCT, MXCN), a leading provider of platform technologies for cell engineering, announces that at the Special Meeting held earlier today in respect of the
RNS Number : 0186C MaxCyte, Inc. 16 June 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Publication of Annual Report and Accounts Gaithersburg, Maryland - 16 June 2021 : MaxCyte (LSE: MXCT, MXCN), a leading provider of cell-engineering platform
